

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
20 March 2025 (20.03.2025)



(10) International Publication Number
WO 2025/059556 A1

(51) International Patent Classification:

A61K 31/519 (2006.01) A61K 9/08 (2006.01)
A61K 47/02 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/046740

(22) International Filing Date:

13 September 2024 (13.09.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/538,720 15 September 2023 (15.09.2023) US

(71) Applicant: **ACROTECH BIOPHARMA INC.** [US/US];
279 PRINCETON HIGHTSTOWN ROAD, EAST
WINDSOR, New Jersey 08520 (US).

(72) Inventors; and

(71) Applicants: **DILEEP, Jami** [IN/IN]; Aurobindo Pharma
Limited, Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1,
Hyderabad Knowledge City, Raidurg Panmaktha, Ranga
Reddy District, Hyderabad, Pin - 500032, Telangana, In-
dia, Hyderabad 500032 (IN). **DASTAGIRI, Madduru**
[IN/IN]; Aurobindo Pharma Limited, Galaxy, Floors: 22-24,
Plot No.1, Survey No.83/1, Hyderabad Knowledge City,
Raidurg Panmaktha, Ranga Reddy District, Hyderabad, Pin
- 500032, Telangana, India, Hyderabad 500032 (IN).

(72) Inventors: **ANVEKAR, Ashish**; c/o Acrotech Bio-
pharma Inc., 279 Princeton Hightstown Road, EAST
WINDSOR, New Jersey 08520 (US). **JANA, Arun**; 279
PRINCETON-HIGHTSTOWN ROAD, EAST WINDSOR,
New Jersey 08520 (US). **VISHNUBHOTLA, Na-
gaprasad**; c/o Acrotech Biopharma Inc., 279 PRINCE-
TON-HIGHTSTOWN ROAD, EAST WINDSOR, New
Jersey 08520 (US). **SIVAKUMARAN, Meenakshisun-
deram**; c/o Acrotech Biopharma Inc., 279 PRINCE-
TON-HIGHTSTOWN ROAD, EAST WINDSOR, New
Jersey 08520 (US).

(74) Agent: **GONCHER, Scott** et al.; c/o Greenberg Traurig,
LLP, One Vanderbilt Avenue, New York, New York 10017
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

— with international search report (Art. 21(3))

(54) Title: COMPOSITIONS COMPRISING PRALATREXATE FOR SUBCUTANEOUS ADMINISTRATION AND METHODS
OF USE THEREOF

(57) Abstract: The present disclosure provides compositions comprising Pralatrexate for subcutaneous administration. The present
disclosure also provides methods of administering the compositions comprising Pralatrexate, as disclosed herein, for the treatment of
disease (e.g., lymphoma).

WO 2025/059556 A1